Loading
A phase 1/2 trial of DM005 in non-small-cell lung cancer and head and neck squamous cell carcinoma, run by Doma Biopharmaceutical（Suzhou）Co., Ltd., now recruiting.
A Study of DM005 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06515990 by Doma Biopharmaceutical（Suzhou）Co., Ltd., with 208 participants planned, started 2024-10-31 and due to reach its primary completion in 2027-03. Interventions recorded: DM005.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/